Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives

摘要

The integration of effective systemic therapies such as immunotherapy with immune checkpoint blockade (ICB) and targeted therapies improves survival outcomes significantly for patients with advanced non-small cell lung cancer (NSCLC). Mounting clinical evidence suggests that the application of radical locoregional therapies (LRT), including surgery and stereotactic body radiotherapy (SBRT) to synchronous oligometastatic NSCLC (SOMNSCLC) improves outcomes beyond those achieved using systemic therapies alone (1,2). However, more precise definitions of SOM-NSCLC are needed to facilitate the care of patients and interpretation of prospective clinical trial results.